Shire to acquire Dyax for initial $5.9 billion

SHARE Shire to acquire Dyax for initial $5.9 billion

LONDON — The Dublin-based drug maker Shire says it will take over U.S. biotechnology firm Dyax in a deal worth an initial $5.9 billion.

The company said Monday that Shire will pay $37.30 in cash for each Dyax share.

Shire also is pursuing Baxalta, the company spun off by Deerfield-based Baxter International in July. Shire has been an buying spree since its deal with AbbVie fell apart last year.

Dyax shareholders will receive an additional $4 a share if certain performance targets are met, which would increase the overall value of the deal by $646 million.

Based in Burlington, Massachusetts, Dyax is specialized in the development of treatments for HAE, a rare genetic disease that can be life-threatening.

The deal is expected to bolster Shire’s role in the treatment of HAE. Dyax has a number of treatment regiments being tested.

The Latest
Police were called to the school at 4460 Old Grand Avenue about 9:30 a.m. Friday when a student reported overhearing another student talking about having a gun, Gurnee police said, and a gun was then found in the student’s locker.
The Hawks produced one of their biggest offensive performances of the season Friday, but they still couldn’t escape their pattern of losses as they fell 3-2 in overtime.
Let’s see what they really have in terms of making a ‘playoff push.’
Intuitive Machines, the private company that made the lander, initially believed its spacecraft was upright when it landed Thursday. But officials said Friday it almost certainly tipped over on its side, covering up some antennas and hampering communications. Intuitive Machines is the first private business to pull off a moon landing, a feat previously achieved by only five countries. And it’s the first U.S. moon landing in more than 50 years.